Trials / Unknown
UnknownNCT04398953
A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)
A Single-arm, Multicenter Phase II Clinical Trial of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 102 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the safety and efficacy of TQ-B3525 tablets in patients with relapsed / refractory mantle cell lymphoma (MCL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ-B3525 | TQ-B3525 tablet administered 20mg orally, once daily in 28-day cycle. |
Timeline
- Start date
- 2020-07-20
- Primary completion
- 2021-09-01
- Completion
- 2021-09-01
- First posted
- 2020-05-22
- Last updated
- 2020-09-11
Locations
39 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04398953. Inclusion in this directory is not an endorsement.